The efficacy and tolerability of monotherapy with micafungin for candidemia and deep-seated candidiasis in adults with cancer.
Antimicrob Agents Chemother. 2014 Mar 17;
Authors: Farmakiotis D, Tarrand JJ, Kontoyiannis DP
The response rate in 58 patients with cancer and candidemia or deep-seated candidiasis treated with micafungin monotherapy was 81%. ICU stay, concomitant nonfungal infections and acute kidney injury were significantly associated with the 30-day crude mortality rate. Severe neutropenia was an independent predictor of micafungin failure. The efficacy and safety of micafungin in cancer patients with invasive candidiasis were comparable to those reported in patients without malignancy, and to cancer patients treated with caspofungin.
PMID: 24637687 [PubMed - as supplied by publisher]